HDAC9 and hyperinsulinemic hypoglycemia, familial, 4: Inflammation, a secondary effect of dystrophin deficiency, is rescued to a greater extent with PCI than with Givinostat, which points out the potential of specific HDAC-targeting therapies compared to pan-HDAC inhibition.